DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the ONYX BIOTEC LIMITED (ONYX) share price today?

ONYX BIOTEC LIMITED (ONYX) is trading at ₹37.6 on the NSE, down 4.93% on the day. Source: DocStoX.

What is the PE ratio of ONYX BIOTEC LIMITED?

ONYX BIOTEC LIMITED has a price-to-earnings (PE) ratio of 13.8 in the Healthcare sector.

What is the market capitalisation of ONYX BIOTEC LIMITED?

ONYX BIOTEC LIMITED has a market capitalisation of approximately ₹67 crore.

ONYX BIOTEC LIMITED

ONYX·NSE·Healthcare

₹37.60▼ -1.95 (-4.93%)

Healthcare · Pharmaceuticals

Revenue compounding 21% a year

52W₹24

₹5445%

Open

₹37.60

High

₹37.60

Low

₹37.60

Prev Close

₹39.55

Volume

2.0K

VWAP

₹37.60

Snapshot

Key fundamentals

Market Cap

₹67 Cr

P/E Ratio

13.77Cheap

P/B Ratio

1.20

EPS

₹2.73

Book Value

₹30.56

ROE

-0.38%Weak

ROCE

12.16%Decent

Dividend Yield

0.00%

Debt / Equity

0.27Low

Face Value

₹10.00

52W High

₹53.90

52W Low

₹24.20

Sector

Healthcare

Industry

Pharmaceuticals

Expensive

None moatHigh uncertainty

Fair value estimate

₹30

▼ 20.2%downside

Trading at ₹38 — 20% above our estimate

BearFair valueBull

₹26₹30₹35

/100

Business quality — Solid

Growth 83Profitability 17Efficiency 10Valuation 89

Plain English

Our view

Revenue compounding 21% a year
Low debt relative to equity
Weak returns on equity (-0%)

Strengths

Low debt relative to equity
Revenue compounding 21% over 3 years
Reasonably priced at 14× earnings
Promoters hold a controlling stake

Risks

Weak returns on equity (-0%)
Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

9% ROE fading to 12% over ~3 yrs, on ₹31 book

₹30

Relative P/E

Needs positive EPS

—

Graham floor

Needs positive EPS

—

Analyst target

No analyst coverage

—

Blended fair value₹30

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Revenue compounding 21% over 3 years
Reasonably priced at 14× earnings
Promoters hold a controlling stake

Bear case

Weak returns on equity (-0%)
Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

13.8Cheap

Below 15× is value territory; above 35× prices in strong growth

ROE

-0.4%Weak

Above 15% is considered healthy for Indian equities

ROCE

12.2%Decent

Above 18% means capital is working hard

Debt/Eq

0.27Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹67 Cr

P/B

1.20

EPS

₹2.73

Div Yield

—

What changed

Recent changes

Foreign investors+1.1% stake last quarter
Domestic institutions+2.4% stake last quarter

What matters

News impact

Overview

Valuation

Attractive

P/E 13.8×

Growth

Strong

+21% rev CAGR

Profitability

Loss-making

-0.4% ROE

Financial health

Rock solid

D/E 0.27

Momentum

N/A

No technicals

Today

Trading activity

Delivery %100.0%

Turnover₹75,200 Cr

Trades1

VWAP₹37.60

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+20.7%

—

10Y

—

Profit

—

10Y

—

EPS

—

10Y

—

Profile

Cons

Company has low interest coverage ratio.
Company has a low return on equity of 6.49% over last 3 years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors bought 1.07 pts; domestic institutions added 2.39 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

65%

Promoter

Promoters

65.1%0.00

Public

23.1%+0.51

FII / FPI

1.1%+1.07

DII

2.4%+2.39

Others

8.3%

Total shareholders

586-54 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter65.10%

FII1.07%

DII2.39%

Public23.15%

Others8.29%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2005, Onyx Biotech Ltd manufactures and sells Sterile Water for Injections, Dry Powder Injections and Dry Syrup for India and overseas, through a B2B business model[1]